{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:00:43Z","timestamp":1761872443203,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015394","name":"American Society for Transplantation and Cellular Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015394","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clml.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T09:29:38Z","timestamp":1694510978000},"page":"874-881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma \u2013 The Oregon Health and Science University Experience"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-1283","authenticated-orcid":false,"given":"Derek","family":"Galligan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staci","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy I.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-4573","authenticated-orcid":false,"given":"Brandon","family":"Hayes-Lattin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7061-0873","authenticated-orcid":false,"given":"Craig","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Spurgeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levanto","family":"Schachter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clml.2023.08.010_bib0001","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2023.08.010_bib0002","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-cell lymphoma project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.010_bib0003","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2023.08.010_bib0004","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2023.08.010_bib0005","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.08.010_bib0006","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.08.010_bib0007","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.08.010_bib0008","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2017.09.002","article-title":"Peripheral T-cell lymphomas: focusing on novel agents in relapsed and refractory disease","volume":"60","author":"Broccoli","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"10168","key":"10.1016\/j.clml.2023.08.010_bib0009","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clml.2023.08.010_bib0010","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2023.08.010_bib0011","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.6004\/jnccn.2020.0053","article-title":"NCCN guidelines insights: T-cell lymphomas, version 1.2021","volume":"18","author":"Horwitz","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 5","key":"10.1016\/j.clml.2023.08.010_bib0012","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.08.010_bib0013","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2023.08.010_bib0014","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2023.08.010_bib0015","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.08.010_bib0016","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.clml.2023.08.010_bib0017","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.08.010_bib0018","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1038\/bcj.2015.43","article-title":"Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma","volume":"5","author":"Rashidi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.clml.2023.08.010_bib0019","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.08.010_bib0020","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodr\u00edguez","year":"2003","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.08.010_bib0021","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.clml.2023.08.010_bib0022","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.clml.2023.08.010_bib0023","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2023.08.010_bib0024","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","article-title":"Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2","volume":"6","author":"Savage","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.clml.2023.08.010_bib0025","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.clml.2023.08.010_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.2022016772","article-title":"Avoiding fratricide: a T-ALL order","volume":"140","author":"Gower","year":"2022","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.clml.2023.08.010_bib0027","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.08.010_bib0028","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jtct.2021.08.016","article-title":"Blood and marrow transplant clinical trials network state of the science symposium 2021: looking forward as the network celebrates its 20th year","volume":"27","author":"Heslop","year":"2021","journal-title":"Transplant Cell Ther"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:23Z","timestamp":1761871403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2152265023002574"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma \u2013 The Oregon Health and Science University Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}